Compare AbCellera Biologics Inc (ABCL) vs Global Payments Inc (GPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Global Payments Inc — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Global Payments Inc trades at $73.12 (market cap $21.22B). The key difference: Global Payments Inc is far larger — about 9× AbCellera Biologics Inc's market cap, and Global Payments Inc pays a 1.29% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GPN | |
|---|---|---|
Market Cap | $2.35B | $21.22B |
Sector | Health | Industrials |
52-Week High | $8.12 | $90.01 |
52-Week Low | $2.78 | $62.47 |
Enterprise Value | $1.99B | $38.94B |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
GPN trades at $77.59, down 1.32% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.96 exceeding expectations. Revenue for 2025 was $7.71 billion, though net income margin turned negative at -7.97% for 2026 projections. Analysts maintain a buy consensus with a $80 price target, citing growth from the Worldpay integration and new AI-powered POS launches.
The stock presents a mixed outlook: positive analyst sentiment and strategic expansions support upside, but margin pressures and rising debt pose risks. Investors should weigh the company's innovation against competitive fintech threats and macroeconomic headwinds affecting transaction volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
